A phase 1 study of CF-602 for the treatment of sexual dysfunction
Phase of Trial: Phase I
Latest Information Update: 26 Aug 2016
At a glance
- Drugs CF 602 (Primary)
- Indications Erectile dysfunction; Sexual function disorders
- Focus Adverse reactions
- 26 Aug 2016 Planned initiation date changed from 1 Oct 2016 to 1 Jan 2017, according to a Can-Fite BioPharma media release.
- 11 Jan 2016 Can-Fite BioPharma plans to file and IND in the fourth quarter of 2016, according to a company media release.
- 29 Jun 2015 According to a company media release, Can-Fite BioPharma plans to file and IND and initiate this study.